Sural nerve biopsy: current role and comparison with serum neurofilament light chain levels

Mariotto, Sara; Carta, Sara; Bozzetti, Silvia; Zivelonghi, Cecilia; Alberti, Daniela; Zanzoni, Serena; Filosto, Massimiliano; Fusina, Simone; Monaco, Salvatore; Castellani, Francesca; Mantovani, Alessandro; Cavallaro, Tiziana; Briani, Chiara; Ferrari, Sergio

doi:10.1007/s00415-020-09949-3

Cited by 15 publications

(18 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these patients, the elevated sNfL levels were not associated with disease activity or progression. Among the six patients with sNfL values above 1 SD, two had diabetes, which is known to influence sNfL levels, 42 and all six patients were within the oldest quartile of the EID4–6 group. Similarly, in a previous study, the sNfL variance was higher among individuals of older age, in a population of patients with RRMS who had been followed with repeated serum sampling.…”

Section: Discussionmentioning

confidence: 99%

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab

et al. 2022

View full text Add to dashboard Cite

Background: Accumulating evidence supports the efficacy of administering natalizumab (NZ) with extended-interval dosing (EID) in patients with relapsing-remitting multiple sclerosis (RRMS). Objectives: We switched NZ dosing from 4-week to 6-week intervals in patients with RRMS, and investigated the effect on serum neurofilament light chain (sNfL) concentrations. Methods: We included two cohorts of patients with RRMS treated with NZ: one received the standard-interval dosing (4 weeks) at baseline, and were switched to 6-week intervals (EID4–6, N = 45). The other cohort received EID (5- or 6-week intervals) both at baseline and during follow-up (EID5/6, N = 25). Serum samples were collected in the EID4–6 cohort at every NZ infusion, for 12 months. The primary outcome was the change in sNfL concentrations after switching to EID. Results: The baseline mean sNfL concentration in the EID4–6 cohort was 10.5 ng/L (standard deviation (SD) = 6.1), and it remained unchanged at 12 months. Moreover, individual sNfL concentrations did not change significantly after extending the NZ dosing intervals. In addition, the EID4–6 and EID5/6 cohorts had similar baseline sNfL concentrations. Conclusion: We concluded that extending the NZ dosing interval did not increase axonal damage, as determined with sNfL, in patients with RRMS.

show abstract

Section: Discussionmentioning

confidence: 99%

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Briefly, neurofilaments are intracellular proteins involved in radial growth and stability of axons that are released, together with other axonal cytoskeletal proteins, into the CSF after neuroaxonal damage. NfL has been demonstrated to be a promising biomarker ( 97 ), useful in different neurological conditions such as MS, dementia, stroke, traumatic brain injury, Parkinson's disease, Huntington disease, encephalitis, peripheral neuropathies, and amyotrophic lateral sclerosis ( 98 – 102 ). On the other hand, GFAP represents the main cytoskeletal protein of mature astrocytes, and it is also involved in regeneration, plasticity, and reactive gliosis ( 103 ).…”

Section: Potential Biomarkers Of Nmosd and Mogadmentioning

confidence: 99%

Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease

et al. 2022

Self Cite

View full text Add to dashboard Cite

The term neuromyelitis optica spectrum disorder (NMOSD) describes a group of clinical-MRI syndromes characterized by longitudinally extensive transverse myelitis, optic neuritis, brainstem dysfunction and/or, less commonly, encephalopathy. About 80% of patients harbor antibodies directed against the water channel aquaporin-4 (AQP4-IgG), expressed on astrocytes, which was found to be both a biomarker and a pathogenic cause of NMOSD. More recently, antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG), have been found to be a biomarker of a different entity, termed MOG antibody-associated disease (MOGAD), which has overlapping, but different pathogenesis, clinical features, treatment response, and prognosis when compared to AQP4-IgG-positive NMOSD. Despite important refinements in the accuracy of AQP4-IgG and MOG-IgG testing assays, a small proportion of patients with NMOSD still remain negative for both antibodies and are called “seronegative” NMOSD. Whilst major advances have been made in the diagnosis and treatment of these conditions, biomarkers that could help predict the risk of relapses, disease activity, and prognosis are still lacking. In this context, a number of serum and/or cerebrospinal fluid biomarkers are emerging as potentially useful in clinical practice for diagnostic and treatment purposes. These include antibody titers, cytokine profiles, complement factors, and markers of neuronal (e.g., neurofilament light chain) or astroglial (e.g., glial fibrillary acidic protein) damage. The aim of this review is to summarize current evidence regarding the role of emerging diagnostic and prognostic biomarkers in patients with NMOSD and MOGAD.

show abstract

“…18,19 Furthermore, a correlation between serum levels of neurofilaments and axonal damage has been demonstrated on nerve biopsies. 20 So far, two preclinical in vivo studies in rats have demonstrated a correlation between serum NfL (sNfL) values and the severity of axonal damage induced by vincristine-based chemotherapy 21 and paclitaxel, as well as cisplatin-induced neurotocixity in rats. 22 Moreover, sNfL levels allow the early identification of axonopathy and have also shown to be a marker that is correlated with the final CIPN severity, mostly in paclitaxel rather than in cisplatin-treated animals.…”

Section: Introductionmentioning

confidence: 99%

“…Data have shown so far that increased levels of NfL in blood and CSF samples can be used as a specific indicator of neuronal injury and disease activity, in various degenerative diseases of the central nervous system, 16,17 as well as in genetic and acquired peripheral neuropathies 18,19 . Furthermore, a correlation between serum levels of neurofilaments and axonal damage has been demonstrated on nerve biopsies 20 …”

Section: Introductionmentioning

confidence: 99%

Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel‐induced peripheral neurotoxicity in breast cancer patients

Karteri

Bruna

Mariotto

et al. 2022

J Peripheral Nervous Sys

Self Cite

View full text Add to dashboard Cite

Our aim was to assess the significance of measuring serum neurofilament light chain (sNfL) levels as a biomarker of paclitaxel‐induced peripheral neurotoxicity (PIPN). We longitudinally measured sNfL in breast cancer patients, scheduled to receive the 12‐weekly paclitaxel‐based regimen. Patients were clinically examined by means of the Total Neuropathy Score‐clinical version (TNSc), while sNfL were quantified, using the highly sensitive Simoa technique, before starting chemotherapy (baseline), after 2 (week 2) and 3 (week 3) weekly courses, and at the end of chemotherapy (week 12). Among 59 included patients (mean age: 53.1 ± 11.5 years), 33 (56%) developed grade 0‐1 and 26 (44%) grade 2‐3 PIPN at week 12. A significant longitudinal increase of sNfL levels from baseline to week‐12 was determined, whereas patients with TNSc grade 2‐3 PIPN had significantly increased sNfL levels at week 12, compared to those with grade 0‐1. receiver‐operated characteristics (ROC) analysis defined a value of NfL of >85 pg/mL at week 3 as the best discriminative determination to predict the development of grade 2‐3 PIPN at week 12 (sensitivity 46.2%, specificity 84.8%). The logistic binary regression analysis revealed that age > 50 years and the cutoff of >85 pg/mL of sNfL levels at week 3 independently predicted the development of grade 2‐3 PIPN at week 12 with a sensitivity of 46%, a specificity of 91%, and a positive and negative predictive values of 75% and 67%, respectively. sNfL levels seem to be a valuable biomarker of neuro‐axonal injury in PIPN. An early increase of this biomarker after a 3‐weekly chemotherapy course can be a predictive marker of final PIPN severity.

show abstract

Sural nerve biopsy: current role and comparison with serum neurofilament light chain levels

Cited by 15 publications

References 16 publications

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab

Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease

Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel‐induced peripheral neurotoxicity in breast cancer patients

Contact Info

Product

Resources

About